Investor presentation
Logotype for Astellas Pharma Inc

Astellas Pharma (4503) Investor presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Astellas Pharma Inc

Investor presentation summary

18 Nov, 2026

Q2 YTD performance and FY2026 outlook

  • Q2 YTD revenue rose 23% YoY and core operating profit rose 50%, driven by Strategic Brands growth and cost optimization.

  • FY2026 forecast raised to ¥2,330B revenue and ¥700B core operating profit, with a 30.0% core operating margin.

  • Strategic Brands FY2026 sales forecast increased by ¥70B to ¥680B; FY2026 SG&A forecast is ¥815B and R&D expense is ¥360B.

  • Q2 YTD Strategic Brands sales reached ¥333.9B, up 51% YoY; PADCEV sales were ¥158.3B, up 55%.

  • XTANDI Q2 YTD sales were ¥533.7B, up 12% YoY; sales are expected to decline in 2H due to the US IRA impact.

Growth strategy and profitability targets

  • FY2026 revenue forecast is ¥2.3T; the outlook targets a pipeline-led inflection from FY2029 and record-high revenue in the mid-2030s.

  • Strategic Brands target 2x FY2025 sales by FY2030; PADCEV, IZERVAY, VYLOY, VEOZAH and XOSPATA are the portfolio’s growth brands.

  • Strategic Brands are projected to exceed 50% of revenue by FY2030, while core operating profit plus R&D is targeted at 50% of revenue.

  • CSP2026 deliverables include ¥4.3T+ cumulative core operating profit before R&D expense and core operating profit before R&D at 50% of revenue.

Pipeline development

  • FY2026–30 plans call for 10+ Phase 3 or pivotal study starts, including 5+ by FY2027; pipeline revenue potential is ~¥1T in the mid-2030s.

  • Pipeline assets are expected to drive growth from FY2029 onward, with R&D base spending averaging 20% of revenue and additional investment of up to 5%.

  • Setidegrasib Phase 3 studies are ongoing in 1L pancreatic cancer and 2L+ NSCLC, with primary analyses anticipated in FY2029 and FY2028, respectively.

  • ASP2138 is in a Phase 3 1L gastric/GEJ study; Phase 1 data showed 62.5% unconfirmed ORR in 1L and responses across low-intermediate and high CLDN18.2 expression.

  • VIR-5500 Phase 1 data in heavily pretreated mCRPC showed 45% ORR among RECIST-evaluable patients; FDA Fast Track designation was granted.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Astellas Pharma